ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1913

Health Literacy and Disease, Clinical, Functional and Management Outcomes in Inflammatory Arthritis: A Systematic Literature Review
Abstract Number: 1931

Health System Improvement in Appropriate Test Utilization Involving ANA Testing in the Inpatient and Outpatient Setting
Abstract Number: 2015

Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy
Abstract Number: 2403

Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
Abstract Number: 1051

Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Abstract Number: 1916

Healthcare Disparities and Clinical Outcomes in Cardiac Sarcoidosis. a Retrospective Cohort Study
Abstract Number: 1026

Healthcare Utilization and Childhood Opportunity Index in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 1343

Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study
Abstract Number: 0522

Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment
Abstract Number: 1958

Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients
Abstract Number: 1090

Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy
Abstract Number: 0617

Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation
Abstract Number: 1720

Herpes Zoster Risk Following Initiation of Immunosuppressive Therapy Among Adults with Rheumatic Disease
Abstract Number: 1886

Heterogeneity of VEXAS Syndrome: A Multicenter Case-series of 299 Cases from the French VEXAS Study Group (FRENVEX)
Abstract Number: 1802

Heterogeneous Neutrophil Subsets Infiltrate Glomeruli of Lupus Nephritis Patients and Are Elevated in the Kidneys and Urine of Sunlight-induced Nephritis Flares

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].